As of November 6, 2026, Oncocyte Corp is a publicly traded company (Nasdaq: IMDX). The largest holder reporting an active stake on Schedule 13D is Broadwood Partners, L.P., at 39.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, April 27, 2026).
Is this your company?
About to sign with, pay or invest in Oncocyte Corp? See the free Snapshot first.
Free to see. No signup.
Is Oncocyte Corp a real, registered company?
- Insight Molecular Diagnostics Inc. files with the SEC under CIK 1642380 (its SEC filings).
- Its shares are listed under the ticker IMDX on Nasdaq (SEC company record).
- Incorporated in California; business address in Nashville, Tennessee, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Oncocyte Corp in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Broadwood Partners, L.P. (filed 2026-04-27).
Who are Oncocyte Corp's owners and officers?
Oncocyte Corp: incorporated in California; business address in Nashville, Tennessee; industry In Vitro & In Vivo Diagnostic Substances (Schedule 13D/A, 2026-04-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-24)
- : Executive Officer (Form D, 2025-02-24)
- : Director (Form D, 2025-02-24)
- : Director (Form D, 2025-02-24)
- : Director (Form D, 2025-02-24)
- : Executive Officer (Form D, 2025-02-24)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-04-27 | Broadwood Partners, L.P. | 39.7% |
| Schedule 13D/A, 2026-02-12 | Broadwood Partners, L.P. | 37.4% |
Questions about who owns Oncocyte Corp
Who owns Oncocyte Corp?
On this page, one holder's latest ownership filing reports 5% or more of Oncocyte Corp: Broadwood Partners, L.P. (39.7%, Schedule 13D/A, filed 2026-04-27).
When did Broadwood Partners, L.P. buy into Oncocyte Corp?
The filings give report dates, not purchase dates. The earliest filing from Broadwood Partners, L.P. on this page is the Schedule 13D/A, filed 2026-02-12, reporting 37.4%; its latest, Schedule 13D/A filed 2026-04-27, reports 39.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Oncocyte Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Oncocyte Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oncocyte Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Oncocyte Corp shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Broadwood Capital Inc., a 10% owner: 50,198,810 shares, 25,118,845 held directly and 25,079,965 indirectly, on a joint filing (Form 4, 2026-04-27).
- Broadwood Partners, L.P., a 10% owner: 50,198,810 shares, 25,118,845 held directly and 25,079,965 indirectly, on a joint filing (Form 4, 2026-04-27).
- , a 10% owner: 50,198,810 shares, 25,118,845 held directly and 25,079,965 indirectly, on a joint filing (Form 4, 2026-04-27).
- , a 10% owner: 3,258,485 shares (10.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-02-11).
- , the chief financial officer: 206,060 shares (0.63% of shares outstanding) (Form 4, 2026-03-30).
Shares outstanding: 32,724,284 as of 2026-08-03, from the company's latest SEC cover page.
How much has Oncocyte Corp raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-24 | $21.74M | $21.74M |
| Form D, 2024-10-08 | $10.20M | $10.20M |
| Form D, 2024-04-25 | $15.81M | $15.81M |
Latest IPO step: Oncocyte Corp filed to go public (S-1, 2025-03-28).
IPO filings: S-1, 2025-03-28; ticker OCX on Nasdaq Capital Market.
Keep reading
More on Oncocyte Corp and the records around it.
Oncocyte Corp elsewhere on the record
- 5%+ stake filings Apr 2026
Companies that share a holder
- Broadwood Partners, L.P. also filed stake reports on 2 other companies: STAAR SURGICAL CO (Mar 2026), Lineage Cell Therapeutics, Inc. (Nov 2025)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/insight-molecular-diagnostics